Larimar started at buy by Truist on Friedreich's ataxia drug
Truist has initiated coverage of Larimar (LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory ...
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
Jupiter is actively exploring additional strategic partnerships to expand JOTROL’s application across other neuroinflammatory and metabolic disorders, including Alzheimer’s disease and longevity ...
Jupiter Neurosciences, Inc.: Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based ...
Optimistic Outlook on Larimar Therapeutics’ Nomlabofusp: Advancements in Clinical Trials for Adolescents with Friedreich’s Ataxia
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...
Biogen's SWOT analysis: neurology giant faces pipeline hurdles, stock outlook mixed
Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...
RI Life Science Hub hosts Neuroscience Symposium
The event brought together 300 researchers, clinicians, industry leaders, and entrepreneurs to highlight their work.
Stockhead on MSN17h
Health Check: Alterity angles for fast-track FDA approval after positive trial results tackling Parkinson’s-like disorder
Alterity plans to seek US FDA fast-track approval after posting positive phase II results for multiple system atrophy ...
‘World’s deadliest food’ kills more than 200 people per year and is still eaten by 500 million
The 'world's deadliest food' is eaten by 500 million people and kills over 200 people a year, this is cassava.
Rhode Island Life Science Hub Convenes Neuroscience Symposium, Showcasing State's Growing Impact on Brain Science
The Rhode Island Neuroscience Symposium gathered 300 researchers, clinicians, industry leaders and entrepreneurs yesterday to ...
Pharmabiz5d
Larimar doses adolescents in nomlabofusp paediatric pharmacokinetic run-in study for patients with Friedreich’s ataxia
Larimar doses adolescents in nomlabofusp paediatric pharmacokinetic run-in study for patients with Friedreich’s ataxia: Bala Cynwyd, Pennsylvania Saturday, January 25, 2025, 15: ...
Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment
Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a market capitalization of $228 million, is a clinical-stage biopharmaceutical ...